| Karen Ruth Mcknight, | |
|
807 Drake Dr, Conway, AR 72034-9399 | |
| (501) 581-3193 | |
| Not Available |
| Full Name | Karen Ruth Mcknight |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Intellectual & Developmental Disabilities |
| Location | 807 Drake Dr, Conway, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164152138 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TM1800X | Psychologist - Intellectual & Developmental Disabilities | 88-23EI (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karen Ruth Mcknight, 807 Drake Dr, Conway, AR 72034-9399 Ph: (501) 581-3193 | Karen Ruth Mcknight, 807 Drake Dr, Conway, AR 72034-9399 Ph: (501) 581-3193 |
News Archive
Individuals in consumer-driven health plans (CDHPs) are more likely than those with traditional coverage to exhibit a number of cost-conscious behaviors, to be more engaged in wellness programs, and to be more inclined to think that financial incentives matter in holding down costs, according to survey results released today by the nonpartisan Employee Benefit Research Institute (EBRI).
Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that affect the proper repair of DNA inside the cell), as determined by an FDA-approved test.
A type of brain cell known as microglia plays a key role in reducing the effects of cocaine in the brain, according to a major study by a team from the Research Institute of the McGill University Health Centre in Montreal.
HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.
In-hospital cardiac arrests (IHCA) represent catastrophic and often terminal events. Despite investments to improve the quality of resuscitation efforts.
› Verified 9 days ago
Susan Sobel, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1014 Main St, Conway, AR 72032 Phone: 501-336-0511 Fax: 501-336-4034 | |
Mrs. Cariann M Bergner-moore, PSYD/PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1312 Donaghey Ave, Conway, AR 72034 Phone: 501-358-6606 | |
Wendi Elliott, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1014 Main St, Conway, AR 72032 Phone: 501-336-0511 Fax: 501-336-4034 | |
Kimberly Ann Callaway Gentry, PHD Psychologist Medicare: Medicare Enrolled Practice Location: 317 Oak St Ste 3, Conway, AR 72032 Phone: 501-358-6396 | |
Susan E Schaefer, PH D Psychologist Medicare: Not Enrolled in Medicare Practice Location: 350 Salem Road, Suite 1, Conway, AR 72034 Phone: 501-336-8300 Fax: 501-329-3572 | |
Sarah Lindeman Root, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1100 Bob Courtway Dr Ste 9, Conway, AR 72032 Phone: 501-812-4268 | |
Ms. Samantha Sewell Short, PSYD, LP Psychologist Medicare: Accepting Medicare Assignments Practice Location: 317 Oak St Ste 3, Conway, AR 72032 Phone: 501-291-3091 Fax: 501-588-0484 |